Key Insights

Highlights

Treatment Research

9 treatments under study, led by Aflibercept

Research Leaders

14 sponsors active, led by Ryhov County Hospital

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1/2 (1)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT06047379Phase 1/2RecruitingPrimary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT05190172Not ApplicableRecruiting

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

Showing all 2 trials

Research Network

Common Treatments

  • Aflibercept1
  • Bevacizumab1
  • Ipilimumab1
  • Nivolumab1
  • Regorafenib1

Active Sponsors

  • Ryhov County Hospital1
  • St. Olavs Hospital1
  • Uppsala University Hospital1
  • Sahlgrenska University Hospital1
  • Ôrebro University Hospital1

Top Investigators

Related Conditions

  • Head And Neck Squamous Cell Carcinoma1
  • Microsatellite Instabilityhigh Colorectal Cancer1
  • Brain Metastases Adult1
  • Esophageal Squamous Cell Carcinoma1
  • Gastroesophageal Junction Adenocarcinoma1

Activity Timeline